TRANSMEDICS GROUP INC (TMDX) Stock Fundamental Analysis

NASDAQ:TMDX • US89377M1099

135.5 USD
+1.68 (+1.26%)
At close: Feb 18, 2026
135.12 USD
-0.38 (-0.28%)
After Hours: 2/18/2026, 8:04:36 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Overall TMDX gets a fundamental rating of 6 out of 10. We evaluated TMDX against 185 industry peers in the Health Care Equipment & Supplies industry. TMDX has only an average score on both its financial health and profitability. TMDX is not overvalued while it is showing excellent growth. This is an interesting combination. This makes TMDX very considerable for growth investing!


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year TMDX was profitable.
  • TMDX had a positive operating cash flow in the past year.
  • In the past 5 years TMDX reported 4 times negative net income.
  • TMDX had negative operating cash flow in 4 of the past 5 years.
TMDX Yearly Net Income VS EBIT VS OCF VS FCFTMDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

  • With an excellent Return On Assets value of 9.70%, TMDX belongs to the best of the industry, outperforming 93.51% of the companies in the same industry.
  • With an excellent Return On Equity value of 25.84%, TMDX belongs to the best of the industry, outperforming 96.76% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 8.75%, TMDX belongs to the top of the industry, outperforming 88.11% of the companies in the same industry.
Industry RankSector Rank
ROA 9.7%
ROE 25.84%
ROIC 8.75%
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
TMDX Yearly ROA, ROE, ROICTMDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300 400

1.3 Margins

  • TMDX has a Profit Margin of 16.20%. This is amongst the best in the industry. TMDX outperforms 93.51% of its industry peers.
  • Looking at the Operating Margin, with a value of 16.94%, TMDX belongs to the top of the industry, outperforming 88.11% of the companies in the same industry.
  • The Gross Margin of TMDX (60.28%) is better than 62.16% of its industry peers.
  • In the last couple of years the Gross Margin of TMDX has remained more or less at the same level.
Industry RankSector Rank
OM 16.94%
PM (TTM) 16.2%
GM 60.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
TMDX Yearly Profit, Operating, Gross MarginsTMDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so TMDX is destroying value.
  • TMDX has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, TMDX has more shares outstanding
  • The debt/assets ratio for TMDX has been reduced compared to a year ago.
TMDX Yearly Shares OutstandingTMDX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
TMDX Yearly Total Debt VS Total AssetsTMDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • TMDX has an Altman-Z score of 5.69. This indicates that TMDX is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 5.69, TMDX belongs to the top of the industry, outperforming 81.62% of the companies in the same industry.
  • TMDX has a debt to FCF ratio of 4.24. This is a neutral value as TMDX would need 4.24 years to pay back of all of its debts.
  • TMDX's Debt to FCF ratio of 4.24 is fine compared to the rest of the industry. TMDX outperforms 80.00% of its industry peers.
  • TMDX has a Debt/Equity ratio of 1.43. This is a high value indicating a heavy dependency on external financing.
  • TMDX has a worse Debt to Equity ratio (1.43) than 78.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF 4.24
Altman-Z 5.69
ROIC/WACC0.91
WACC9.63%
TMDX Yearly LT Debt VS Equity VS FCFTMDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 7.69 indicates that TMDX has no problem at all paying its short term obligations.
  • The Current ratio of TMDX (7.69) is better than 88.11% of its industry peers.
  • TMDX has a Quick Ratio of 7.13. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 7.13, TMDX belongs to the top of the industry, outperforming 89.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.69
Quick Ratio 7.13
TMDX Yearly Current Assets VS Current LiabilitesTMDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • TMDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 162.77%, which is quite impressive.
  • The Revenue has grown by 41.20% in the past year. This is a very strong growth!
  • Measured over the past years, TMDX shows a very strong growth in Revenue. The Revenue has been growing by 79.64% on average per year.
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%

3.2 Future

  • TMDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.25% yearly.
  • TMDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.23% yearly.
EPS Next Y163.58%
EPS Next 2Y71.04%
EPS Next 3Y53.35%
EPS Next 5Y33.25%
Revenue Next Year39.6%
Revenue Next 2Y29.73%
Revenue Next 3Y25.56%
Revenue Next 5Y21.23%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
TMDX Yearly Revenue VS EstimatesTMDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
TMDX Yearly EPS VS EstimatesTMDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2 4 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • TMDX is valuated quite expensively with a Price/Earnings ratio of 54.86.
  • Based on the Price/Earnings ratio, TMDX is valued a bit cheaper than 67.57% of the companies in the same industry.
  • TMDX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.27.
  • TMDX is valuated quite expensively with a Price/Forward Earnings ratio of 45.86.
  • 68.11% of the companies in the same industry are more expensive than TMDX, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of TMDX to the average of the S&P500 Index (28.16), we can say TMDX is valued expensively.
Industry RankSector Rank
PE 54.86
Fwd PE 45.86
TMDX Price Earnings VS Forward Price EarningsTMDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TMDX indicates a somewhat cheap valuation: TMDX is cheaper than 67.03% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of TMDX indicates a somewhat cheap valuation: TMDX is cheaper than 76.22% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 38.39
EV/EBITDA 37.96
TMDX Per share dataTMDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • TMDX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • TMDX's earnings are expected to grow with 53.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.34
PEG (5Y)N/A
EPS Next 2Y71.04%
EPS Next 3Y53.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • TMDX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TRANSMEDICS GROUP INC

NASDAQ:TMDX (2/18/2026, 8:04:36 PM)

After market: 135.12 -0.38 (-0.28%)

135.5

+1.68 (+1.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-29
Earnings (Next)02-24
Inst Owners111.19%
Inst Owner Change-2.55%
Ins Owners2.95%
Ins Owner Change-0.16%
Market Cap4.63B
Revenue(TTM)566.35M
Net Income(TTM)91.77M
Analysts83
Price Target148.92 (9.9%)
Short Float %23.79%
Short Ratio11.2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.22%
Min EPS beat(2)84.39%
Max EPS beat(2)100.04%
EPS beat(4)4
Avg EPS beat(4)92.06%
Min EPS beat(4)16.42%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)202.42%
EPS beat(12)10
Avg EPS beat(12)118.6%
EPS beat(16)12
Avg EPS beat(16)90.24%
Revenue beat(2)1
Avg Revenue beat(2)0.71%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)4.34%
Revenue beat(4)3
Avg Revenue beat(4)5.83%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)7.35%
Revenue beat(12)10
Avg Revenue beat(12)12.14%
Revenue beat(16)14
Avg Revenue beat(16)18.13%
PT rev (1m)0.06%
PT rev (3m)-0.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.04%
EPS NY rev (1m)0%
EPS NY rev (3m)0.59%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)0.1%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)-0.08%
Valuation
Industry RankSector Rank
PE 54.86
Fwd PE 45.86
P/S 8.18
P/FCF 38.39
P/OCF 25.96
P/B 13.04
P/tB 13.55
EV/EBITDA 37.96
EPS(TTM)2.47
EY1.82%
EPS(NY)2.95
Fwd EY2.18%
FCF(TTM)3.53
FCFY2.6%
OCF(TTM)5.22
OCFY3.85%
SpS16.57
BVpS10.4
TBVpS10
PEG (NY)0.34
PEG (5Y)N/A
Graham Number24.04
Profitability
Industry RankSector Rank
ROA 9.7%
ROE 25.84%
ROCE 11.08%
ROIC 8.75%
ROICexc 18.94%
ROICexgc 19.61%
OM 16.94%
PM (TTM) 16.2%
GM 60.28%
FCFM 21.29%
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score7
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF 4.24
Debt/EBITDA 4.16
Cap/Depr 224.51%
Cap/Sales 10.19%
Interest Coverage 250
Cash Conversion 146.57%
Profit Quality 131.41%
Current Ratio 7.69
Quick Ratio 7.13
Altman-Z 5.69
F-Score7
WACC9.63%
ROIC/WACC0.91
Cap/Depr(3y)951.97%
Cap/Depr(5y)615.69%
Cap/Sales(3y)34.99%
Cap/Sales(5y)23.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
EPS Next Y163.58%
EPS Next 2Y71.04%
EPS Next 3Y53.35%
EPS Next 5Y33.25%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
Revenue Next Year39.6%
Revenue Next 2Y29.73%
Revenue Next 3Y25.56%
Revenue Next 5Y21.23%
EBIT growth 1Y205.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year317.92%
EBIT Next 3Y87.46%
EBIT Next 5Y68.49%
FCF growth 1Y187.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y802.91%
OCF growth 3YN/A
OCF growth 5YN/A

TRANSMEDICS GROUP INC / TMDX FAQ

Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?

ChartMill assigns a fundamental rating of 6 / 10 to TMDX.


Can you provide the valuation status for TRANSMEDICS GROUP INC?

ChartMill assigns a valuation rating of 5 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.


How profitable is TRANSMEDICS GROUP INC (TMDX) stock?

TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 5 / 10.


How financially healthy is TRANSMEDICS GROUP INC?

The financial health rating of TRANSMEDICS GROUP INC (TMDX) is 6 / 10.